BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Nosology
,
Doxycycline
,
rs4950928
,
ERBB2
,
Metabolism of xenobiotics
,
Ischemia
,
Retina
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
receptors bombesin
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Disruption of neuromedin B receptor improves mitochondrial oxidative phosphorylation capacity in gas…
Discovery of Dimethyl Shikonin Oxime 5a, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for…
Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Ro…
Advances of radiolabeled GRPR ligands for PET/CT imaging of cancers.
Neuromedin B receptor disruption impairs adipogenesis in mice and 3T3-L1 cells.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Pilot Trial to Assess 68Ga Bombesin PET/CT (NeoB) Imaging for Staging of Breast Cancer
Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP)
68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide…
68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ